annb0t
Top 20
Approval demonstrates the potential of Zilosul⢠to address an unmet medical need in OA which effects more than 72 million people in the US, EU5, and Canada
KEY HIGHLIGHTS
FDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosulâ¢/PPS) offers pathways to expedite development of Paradigm's osteoarthritis clinical program. FDA Fast Track acknowledges osteoarthritis as a serious disease with unmet needs and the potential for PPS to offer a treatment for OA. Fast Track designati...
>>> Read more: FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
KEY HIGHLIGHTS
FDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosulâ¢/PPS) offers pathways to expedite development of Paradigm's osteoarthritis clinical program. FDA Fast Track acknowledges osteoarthritis as a serious disease with unmet needs and the potential for PPS to offer a treatment for OA. Fast Track designati...
>>> Read more: FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
